Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial

Camilla Fuchs Andersen, Massar Omar, Andreas Glenthoj, Daniel El Fassi, Holger J. Moller, Jorgen A. Lindholm Kurtzhals, Bjarne Styrishave, Caroline Kistorp, Christian Tuxen, Mikael K. Poulsen, Jens Faber, Lars Køber, Finn Gustafsson, Jacob E. Moller, Morten Schou, Jesper Jensen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

85 Downloads (Pure)


Aims It remains unknown whether the consistently observed increase in haematocrit with sodium-glucose cotransporter 2 inhibitors is caused by diuresis-associated haemoconcentration or increased erythropoiesis. We aimed to investigate the early effect of empagliflozin on erythropoiesis and iron metabolism in patients with heart failure with reduced ejection fraction (HFrEF). Methods and results The Empire HF was a double-blind, randomized, placebo-controlled trial. Patients with a left ventricular ejection fraction (LVEF) 0.05). Conclusion These findings suggest that empagliflozin increases erythropoiesis and augments early iron utilization in patients with HFrEF. These mechanisms may contribute to the cardioprotective properties of empagliflozin.
TidsskriftEuropean Journal of Heart Failure
Udgave nummer2
Sider (fra-til)226-234
StatusUdgivet - feb. 2023


Dyk ned i forskningsemnerne om 'Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial'. Sammen danner de et unikt fingeraftryk.